Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...

Parabilis Medicines raised $305 million in a Series F round led by RA Capital, Fidelity and Janus Henderson, with crossover ...

As we enter 2026, U.S. equities are expected to enter a phase marked by several complexities following the outsized gains in ...

Vividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, today announced the publication of a ...

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: ...

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a drug discovery company developing breakthrough medicines through its AI-enhanced computational drug discovery engine, today announced it ...

For the first time, scientists have captured how new antiviral drugs halt the herpes virus in real time as it tries to ...

The core of the revaluation stems from a strategic move by Gilead Sciences in the second half of December 2025. The pharmaceutical giant exercised its option to secure exclusive licensing rights to ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. Chart does not reflect ...

Multi-omics analyses reveal redundant functions of yeast mRNA decapping activators Scd6 and Edc3 in facilitating recruitment of helicase Dhh1 and accelerating degradation of transcripts required for ...